GENE ONLINE|News &
Opinion
Blog

Astellas Pharma
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
Astellas Trains Sights On Iveric Bio In $5.9 Billion Acquisition
2023-05-03
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Astellas Clears Primary Endpoints In Prostate Cancer And Menopause Trials
2023-03-14
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
2023-01-12
Astellas’ Zolbetuximab Meets Phase 3 Endpoints In Gastric And GEJ Cancers
2022-12-16
Astellas’ Claudin 18.2 Antibody Shows Its Teeth In GEJ Cancer Trial
2022-11-17
Astellas Invests $50 Million In Taysha, Licenses Two CNS Gene Therapies
2022-10-25
EMA Begins Regulatory Review For Astellas’ Fezolinetant
2022-10-03
Further Clinical Trial Results Reinforce Prior Findings For Astellas’ Menopause Treatment
2022-09-05
Astellas and Sutro Team Up for Immunostimulatory Antibody-Drug Conjugates (iADCs)
2022-06-28
Astellas Ups Production of Gene Therapies With New Carolina Plant
2022-06-09
Astellas Ditches Gene Therapies, with Losses Exceeding $390 Million
2022-04-25
Astellas Reveals Early Safety Data of Gene Therapy for Pompe Disease
2022-02-09
Astellas Taps Dyno in $1.6+ Billion Deal to Develop AAV Gene Therapies
2021-12-02
1 2 3
LATEST
BIO 2023 Coming to Boston, with Over 60 Taiwanese Organizations to Share their Achievements
2023-06-02
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications
2023-06-02
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
Scroll to Top